Effects of tocilizumab on the efficacy, immunoglobulin and helper T cells in patients with rheumatoid arthritis
10.3969/j.issn.1006-0111.201905023
- VernacularTitle:托珠单抗对类风湿关节炎患者疗效、免疫球蛋白及辅助性T细胞水平的影响
- Author:
Qin DU
1
;
Hongdi XU
2
Author Information
1. Internal Medicine Department, Zhejiang Youth Hospital, Hangzhou 310000, China.
2. Internal Medicine Department, Zhejiang Youth Hospital, Hangzhou 310000, China.34060152@qq.com
- Keywords:
tocilizumab;
rheumatoid arthritis;
immunoglobulin;
Th1;
Treg
- From:
Journal of Pharmaceutical Practice
2020;38(1):71-73
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of tocilizumab on the efficacy, immunoglobulin and helper T cells in patients with rheumatoid arthritis. Methods 90 patients with rheumatoid arthritis in our hospital were randomly divided into control group and observation group, 45 cases in each group. The patients in the control group were treated with infliximab and methotrexate. The patients in the observation group were treated with tocilizumab and methotrexate. The patients in the two groups were both treated for 6 months. The clinical efficacy of the two groups was compared after treatment. Before and after treatment, the serum levels of immunoglobulin, Th-1 and Treg of patients in two groups were measured. Results The results showed that after treatment, the situation of morning stiffness, joint pressure pain and joint swelling of the patients in the two groups were improved, and the improvement of morning stiffness, joint pressure pain and joint swelling in the observation group was greater (P<0.05). The levels of IgG and Th1 cells in the serum of patients in the two groups significantly decreased, and the levels of IgG and Th1 cells in the serum of the patients in the observation group were significantly lower than that of the control group (P<0.05). The serum level of Treg cells in the serum of patients in the two groups increased significantly, and the level of Treg in the serum of patients in the observation group was significantly higher than that in the control group (P<0.05). Conclusion Topazumab could effectively improve the clinical symptoms of patients with rheumatoid arthritis, and improve the immune dysfunction of the patients with better clinical efficacy.
